Dec 19, 2009
NCT01029054: Phase 1/2: Carfilzomib and Lenalidomide With Dexamethasone Combination in NDMM
NCT01029054: Phase 1/2: Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple...
106
Dec 18, 2009
NCT00833833: Phase 1/2: MTD, Safety, and Efficacy of Pomalidomide (CC-4047) +/- Dexamethasone RRMM
NCT00833833: Phase 1/2: MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With...
529
Dec 16, 2009
A Meta-Analysis: Tandem Vs Single Autologous Hematopoietic Cell Transplantation Myeloma - JNCI 2009
Tandem Versus Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and...
16
Dec 16, 2009
Phase 2: Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed MM
Leukemia; 2009 Jul Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in...
89
Dec 12, 2009
NCT01023308: Phase 3 - Panobinostat or Placebo With Bortezomib & Dex in Relapsed Myeloma PANORAMA-1
PANORAMA Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome...
246
Dec 4, 2009
NCT00833560: Phase 2: A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients NDMM
German DSMM Xia trial NCT00833560: Phase 2: A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated...
61